Clinical significance of combined detection of Survivin and MUC7 in urine in the detection of bladder cancer

doi:10.3877/cma.j.issn.1674-3253.2019.03.006

Abstract

Abstract:

Objective

To investigate the clinical value of detection of Survivin and mucin 7 (MUC7) in urine in the diagnosis of bladder cancer.

Methods

Seventy-five patients with bladder cancer, 38 patients with benign diseases of urinary system and 20 healthy volunteers were enrolled, and three urine specimens were collected in all patients. The clinical value of three methods in the diagnosis of bladder cancer was analyzed and compared by detecting the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of Survivin, MUC7 and cytology in urine respectively.

Results

The sensitivity and specificity of Survivin in the diagnosis of bladder cancer were 93.3% and 98.3%, respectively. The sensitivity and specificity of MUC7 in the diagnosis of bladder cancer were 80% and 100%, respectively. The sensitivity and specificity of cytology in the diagnosis of bladder cancer were 66.7% and 100%, respectively. The sensitivity and specificity of Survivin combined with MUC7 were 98.7% and 100%, respectively. The significant differences were observed in the sensitivity when comparing Survivin or MUC7 with the cytology respectively (P<0.05). The accuracy of Survivin combined with MUC7, Survivin MUC7 and cytology were 99.2%, 95.5%, 88.7% and 81.2.3%, respectively, which had obviously increasement compared with cytology group (78.3%) (P<0.05, respectively).

Conclusions

Combination of Survivin and MUC7 can improve the sensitivity and accuracy in diagnosis of bladder cancer.

Key words: Bladder cancer, Survivin, Mucin 7, Urine, Tumor markers

Zhenxiang Lin, Xiaoyong Pu, Jiumin Liu, Xuecheng Bi, Teng Li, Jianxiong Fang, Xiewu Zhang. Clinical significance of combined detection of Survivin and MUC7 in urine in the detection of bladder cancer[J]. Chinese Journal of Endourology(Electronic Edition), 2019, 13(03): 166-169.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2019.03.006

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2019/V13/I03/166

Figures/Tables 3

References 16

[1]	Apollo A, Ortenzi V, Scatena C, et al. Molecular characterization of low grade and high grade bladder cancer[J]. PLoS One. 2019, 14(1): e0210635.
[2]	钟文文，胡成，李科, 等. 原位膀胱癌动物模型的建立及其体外活体成像检测[J/CD].中华腔镜泌尿外科杂志(电子版), 2016, 10(4): 56-59.
[3]	谢伟槟，刘皓，孔坚秋, 等. 膀胱癌盆腔淋巴结转移的规律及影响因素分析[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2018, 12(6): 397-401.
[4]	何威，徐兆平，谢欣,等. 机器人根治性膀胱切除术加双U原位膀胱术治疗肌层浸润性膀胱癌 [J/CD]. 中华腔镜泌尿外科杂志(电子版), 2016, 12(6): 15-18.
[5]	Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics [J]. CA Cancer J Clin, 2001, 51(1): 15-36.
[6]	Pu XY, Wang ZP, Chen YR, et al. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine [J]. J Cancer Res Clin Oncol, 2008, 134(6): 659-665.
[7]	March-Villalba JA, Ramos-Soler D, Soriano-Sarrió P, et al. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973) [J]. Urol Oncol, 2019 , 37(2): 158-165.
[8]	Moussa O, Abol-Enein H, Bissada N K, et al. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer [J]. J Urol, 2006, 175(6): 2312-2316.
[9]	Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer [J]. JAMA, 2001, 285 (3): 324-328.
[10]	廖洪，唐国民，张荣荣, 等. 膀胱移行细胞癌患者尿脱落细胞中MUC7和CK20的表达及其临床意义[J]. 四川医学, 2006, 27(6): 558-560.
[11]	Retz M, Lehmann J, Roder C, et al. Differential mucin MUC7 gene expression in invasive bladder carcinoma in contrast to uniform MUC1 and MUC2 gene expression in both normal urothelium and bladder carcinoma [J]. Cancer Res, 1998, 58(24): 5662-5666.
[12]	Ku JH, Godoy G, Amiel GE, et al. Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review[J]. BJU Int, 2012, 110(5): 630-636.
[13]	Wang H, Xi X, Kong X, et al. The expression and significance of survivin mRNA in urinary bladder carcinomas [J]. J Cancer Res Clin Oncol, 2004, 130(8): 487-490.
[14]	Muhammad AS, Mungadi IA, Ndodu ED, et al. Performance of urinary survivin as a non-invasive molecular marker of bladdercarcinoma ina schistosomiasis endemic area [J]. Ghana Med J, 2018, 52(2): 74-78.
[15]	Okegawa T, Kinjo M, Horie S, et al. Detection of mucin 7 gene expression in efoliated cells in urine from patients with bladder tumor [J]. Urology, 2003, 62(1): 182-186.
[16]	Kinjo M, Okegawa T, Horie S, et al. Detection of circulating MUC7-positive cells by reverse transcription-polymerase chain reaction in bladder cancer patients [J]. Int J Urol. 2004, 11(1): 38-43.

?	例数	Survivin	MUC7	尿脱落细胞学
膀胱肿瘤组	75	70（97.2）	60（80）	50（66.7）
良性疾病组	38	01（2.6）	00（0）0	00（0）00
健康对照组	20	00（0）	00（0）0	00（0）00

?	例数	Survivin	MUC7	尿脱落细胞学
膀胱肿瘤组	75	70（97.2）	60（80）	50（66.7）
良性疾病组	38	01（2.6）	00（0）0	00（0）00
健康对照组	20	00（0）	00（0）0	00（0）00

?	敏感性	特异性	阳性预测值	阴性预测值	准确性
Survivin	70/75（93.3）	57/58（98.3）	72/73（98.6）	57/62（91.9）	127/133（95.5）
MUC7	60/75（80）0.	58/58（100）	60/60（100）	58/73（79.5）	118/133（88.7）
尿脱落细胞学	50/75（66.7）	58/58（100）	50/50（100）	58/83（69.9）	108/133（81.2）
Survivin+MUC7	74/75（98.7）	58/58（100）	74/74（100）	58/59（98.3）	132/133（99.2）

?	敏感性	特异性	阳性预测值	阴性预测值	准确性
Survivin	70/75（93.3）	57/58（98.3）	72/73（98.6）	57/62（91.9）	127/133（95.5）
MUC7	60/75（80）0.	58/58（100）	60/60（100）	58/73（79.5）	118/133（88.7）
尿脱落细胞学	50/75（66.7）	58/58（100）	50/50（100）	58/83（69.9）	108/133（81.2）
Survivin+MUC7	74/75（98.7）	58/58（100）	74/74（100）	58/59（98.3）	132/133（99.2）

?		例数	Survivin	MUC7
分级		?	?	?
?	G1	20	19（95.0）	15（75.0）
?	G2	25	24（96.0）	22（88.0）
?	G3	30	27（90.0）	28（93.3）
分期		?	?	?
?	Tis	5	04（80.0）	03（60.0）
?	Ta	22	21（95.5）	18（81.8）
?	T1	27	26（96.3）	24（88.9）
?	T2	14	13（92.9）	13（92.9）
?	T3	7	06（85.7）	07（100.0）

Please choose a citation manager

Content to export